Pricing of reimbursable pharmaceuticals in Switzerland: Implementation of amended federal ordinances as of March 1st 2017
In 2015, in terms of value, more than 82.6% (CHF 4 445 million) of the total pharmaceutical market in Switzerland consisted of reimbursable medicines, most of which were prescription-only products at the same time. These figures demonstrate the importance of this market to the industry.
In Switzerland, as in many other countries, the price to the public of reimbursable medicine (maximum price that is reimbursed by the mandatory health insurance) is not freely established on the market, but subject to a complex set of regulatory interventions. In order for a pharmaceutical to be reimbursable, it has to be admitted to the so-called Specialties List ("SL") drawn up by the Federal Office of Public Health ("FOPH"). The criteria for a pharmaceutical to be included in the SL are efficacy, suitability and cost-effectiveness of the medicine concerned.
Read more by clicking on the link below: